Has Dana White confirmed he uses TRT?

White has publicly discussed using testosterone as part of his health overhaul, including in podcast interviews from 2023. He has not disclosed specific formulations, doses, or whether he remains on therapy. Detailed protocol claims are speculated.

What happens to testosterone levels when you stop TRT?

Circulating testosterone drops to pre-treatment or below-baseline levels within days to weeks of stopping. Endogenous production recovery depends on age, duration of therapy, and individual HPG axis responsiveness. Some men recover fully within 3 to 6 months. Others, particularly older men on long-term therapy, may not.

Can you stop TRT cold turkey?

Abrupt cessation is not medically dangerous in the acute sense, but it produces a symptomatic trough that many men find intolerable. A supervised taper with lab monitoring is the approach most endocrinologists recommend.

Does TRT cause heart problems?

The TRAVERSE trial (2023) found no significant increase in major cardiovascular events in hypogonadal men on TRT compared to placebo. Ongoing monitoring of hematocrit, lipids, and blood pressure remains standard practice for anyone on long-term therapy.

Is long-term TRT safe?

For men with documented hypogonadism, current evidence and Endocrine Society guidelines support long-term use with appropriate monitoring. The primary risks to manage are polycythemia, cardiovascular health, and prostate screening.

Dana White, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What Dana White Has Actually Said

Dana White, 56, has spoken publicly about testosterone use in interviews and on social media. In a 2023 appearance on the Full Send Podcast, White discussed his broader health overhaul, which included rapid weight loss and hormone optimization. He has acknowledged using testosterone as part of that process.

What White has not publicly confirmed: his specific testosterone formulation, dosing schedule, whether he uses injectable or topical preparations, or whether he has ever discontinued therapy. Any claims about those details remain speculated and should be treated accordingly.

White's body composition changed visibly between late 2022 and mid-2024, a transformation covered extensively by ESPN, MMA Fighting, and other outlets. He has attributed these changes to a combination of dietary shifts, peptide therapies, and hormone management. The exact role TRT played in that recomposition is not publicly confirmed beyond White's general acknowledgment.

At a glance

Status: Dana White has publicly acknowledged using TRT; specific protocol details are not confirmed
Drug family: Testosterone replacement therapy (TRT)
Key clinical question: What happens to the body when exogenous testosterone is discontinued after sustained use?
Why it matters: The UFC president's public posture on TRT shapes how millions of combat-sport fans think about hormone therapy

The Clinical Reality of Stopping TRT

For any man on testosterone replacement, discontinuation is not a simple off-switch. The hypothalamic-pituitary-gonadal (HPG) axis, the feedback loop responsible for endogenous testosterone production, suppresses during exogenous administration. How quickly (or whether) it recovers depends on several factors the HealthRX Medical Team considers critical.

HPG Axis Suppression and Recovery

Exogenous testosterone signals the hypothalamus to reduce gonadotropin-releasing hormone (GnRH) output. This cascades downstream: the pituitary secretes less luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and the testes reduce or cease endogenous production. A 2004 study in the Journal of Clinical Endocrinology & Metabolism documented that LH and FSH suppression occurs within weeks of initiating testosterone therapy and can persist for months after cessation.

Recovery timelines vary. Younger men with shorter treatment durations may see LH normalize within 4 to 12 weeks. Men over 50 who have used testosterone for years may experience incomplete recovery, a state sometimes called secondary hypogonadism induced by prior therapy. A 2019 review in Fertility and Sterility found that spermatogenesis recovery took a median of 6 months, with some men requiring over a year.

Symptoms During the Gap

The period between stopping exogenous testosterone and recovering endogenous production creates a hormonal trough. During this window, men commonly report:

Fatigue and reduced exercise tolerance
Loss of lean mass and increased adiposity
Depressed mood or irritability
Decreased libido
Sleep disturbances

These symptoms mirror classic hypogonadism and are not psychological. They reflect genuinely low circulating testosterone during the recovery period. For someone like White, who has publicly credited his regimen with dramatic physical changes, this gap period would represent a real physiological challenge, not a minor inconvenience.

The HealthRX Medical Team's Discontinuation Framework

The HealthRX Medical Team views TRT discontinuation through three clinical tiers:

Tier 1: Supervised taper with post-cycle monitoring. Rather than abrupt cessation, a gradual dose reduction over 4 to 8 weeks can ease the transition. Serial labs (total testosterone, free testosterone, LH, FSH, estradiol) at weeks 4, 8, and 16 post-cessation allow clinicians to track recovery and intervene if needed.

Tier 2: Adjunctive recovery agents. Some endocrinologists use selective estrogen receptor modulators (SERMs) like clomiphene citrate off-label to stimulate the pituitary during recovery. A 2015 study published in BJU International demonstrated that clomiphene increased endogenous testosterone in hypogonadal men, though long-term data on this approach remains limited.

Tier 3: Accepting long-term therapy. For men with confirmed primary hypogonadism (testicular failure) or those whose HPG axis does not recover after a supervised trial off therapy, indefinite TRT may be the appropriate clinical decision. The Endocrine Society's 2018 guidelines support ongoing treatment when hypogonadism is persistent and symptomatic.

Long-Term Considerations for Men Who Continue

If a man opts to stay on TRT, or if his clinical picture requires it, the monitoring obligations are well established.

Cardiovascular Risk

The relationship between TRT and cardiovascular events has been debated for over a decade. The TRAVERSE trial, published in The New England Journal of Medicine in 2023, was the first large randomized trial powered for cardiovascular outcomes. It found that testosterone replacement in men 45 to 80 years old with hypogonadism and preexisting or high risk of cardiovascular disease did not significantly increase the incidence of major adverse cardiac events compared with placebo. This was reassuring but not a blanket safety guarantee; the trial excluded men with recent stroke or MI.

For a man in his mid-50s with a public history of health concerns (White disclosed a serious health scare in 2023), ongoing cardiac monitoring remains standard of care. The HealthRX Medical Team recommends annual lipid panels, hematocrit checks every 6 months, and baseline echocardiography for men on TRT with cardiovascular risk factors.

Polycythemia and Hematocrit

Testosterone stimulates erythropoiesis. Hematocrit levels above 54% increase thrombotic risk, and this remains the most common reason clinicians adjust or pause TRT dosing. Monitoring every 3 to 6 months is the standard recommendation from the Endocrine Society.

Prostate Considerations

The old concern that testosterone "feeds" prostate cancer has been substantially revised. Current evidence, including a 2016 meta-analysis in Medicine, does not support the claim that TRT increases prostate cancer incidence. Monitoring with PSA and digital rectal exam remains appropriate, particularly for men over 50, but fear of prostate cancer alone is no longer considered a contraindication to therapy.

Bone Density

One underappreciated benefit of sustained TRT is its effect on bone mineral density. Testosterone supports osteoblast activity, and the Testosterone Trials (TTrials) published in JAMA Internal Medicine showed significant increases in volumetric bone mineral density in older hypogonadal men treated for 12 months. Discontinuation removes this protective effect, which is particularly relevant for men over 55.

Why the UFC President's Stance Matters

White is not just a celebrity user of health optimization protocols. He runs the organization that banned TRT therapeutic use exemptions (TUEs) in 2014, a decision that reshaped how combat sports regulate hormone therapy. His personal openness about testosterone use while presiding over an organization that prohibits it in competition creates a tension that keeps TRT in the MMA conversation.

This is exactly why clinical precision matters. The public discussion around White and TRT often conflates replacement-dose therapy for documented hypogonadism with supraphysiological dosing for performance. These are distinct clinical scenarios with different risk profiles, different monitoring requirements, and different ethical considerations.

The HealthRX Medical Team's position: any man considering TRT, starting it, or thinking about stopping it should work with an endocrinologist or urologist who specializes in male hormone health. The decision to discontinue is as medically significant as the decision to start.

Frequently asked questions

›

References

Endocrine Society. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37334136/
Snyder PJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone. JAMA Intern Med. 2017. https://pubmed.ncbi.nlm.nih.gov/28055048/
Katz DJ, et al. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism. BJU Int. 2015. https://pubmed.ncbi.nlm.nih.gov/25532710/
Liu PY, et al. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception. Fertil Steril. 2019. https://pubmed.ncbi.nlm.nih.gov/30316415/
Cui Y, et al. The effect of testosterone replacement therapy on prostate cancer. Medicine. 2016. https://pubmed.ncbi.nlm.nih.gov/26871792/